IP Library › Patent Application 15470468
Patent Application
App. No. 15/470,468

METHODS AND COMPOSITIONS FOR TREATMENT OF SKIN DISORDERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/470,468
Abstract

The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental TNFα activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental TNFα activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. The invention further provides methods for determining the efficacy of a human TNFα antibody, or antigen-binding portion thereof, for the treatment of a skin disorder associated with detrimental TNFα activity, such as psoriasis.

Claims (4)

1 . A method for treating a skin disorder associated with detrimental TNFα activity in a subject who has failed to respond to or has lost responsiveness to a biologic therapy, comprising administering to the subject who has failed to respond to or has lost responsiveness to the biologic therapy, a human TNFα antibody, or an antigen-binding portion thereof, such that the skin disorder is treated.

2 . A method of determining the efficacy of a human TNFα antibody, or an antigen binding portion thereof, for treating psoriasis in a subject who has failed to respond to or has lost responsiveness to a biologic therapy comprising,

determining the PASI50 response of a patient population who has failed to respond to or has lost responsiveness to a biologic therapy, and who were administered the human TNFα antibody, or antigen binding portion thereof,

wherein a statistically significant improvement in the PASI50 of the patient population indicates that the TNFα inhibitor is effective for treating psoriasis in the subject.